Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 535,203 | 920,359 | 646,508 | 604,214 | 809,102 |
| Marketable Securities | 503,481 | 488,032 | 398,656 | 244,965 | 236,121 |
| Receivables | 1,611,620 | 1,643,872 | 1,751,971 | 1,865,221 | 1,467,793 |
| Inventories | 399,356 | 345,620 | 316,073 | 303,294 | 238,578 |
| TOTAL | $3,180,188 | $3,501,689 | $3,209,225 | $3,133,379 | $2,915,095 |
| Non-Current Assets | |||||
| PPE Net | 2,083,421 | 1,872,167 | 1,772,923 | 1,666,391 | 1,594,120 |
| Investments And Advances | 864,260 | 777,906 | 589,852 | 555,210 | 632,162 |
| Other Non-Current Assets | 845,597 | 676,257 | 632,906 | 549,480 | 467,755 |
| TOTAL | $3,793,278 | $3,326,330 | $2,995,681 | $2,771,081 | $2,694,037 |
| Total Assets | $6,973,466 | $6,828,019 | $6,204,906 | $5,904,460 | $5,609,132 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 879,096 | 714,916 | 759,643 | 733,276 | 644,112 |
| Other current liabilities | 1,178 | 3,586 | 3,695 | 13,508 | 13,563 |
| TOTAL | $1,241,495 | $961,185 | $951,563 | $919,724 | $811,162 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 231,664 | 242,683 | 188,225 | 172,940 | 153,487 |
| Other Non-Current Liabilities | 100,385 | 135,700 | 119,523 | 120,993 | 115,535 |
| TOTAL | $1,282,726 | $1,375,587 | $1,176,837 | $1,219,654 | $1,143,133 |
| Total Liabilities | $2,524,221 | $2,336,772 | $2,128,400 | $2,139,378 | $1,954,295 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 106,081 | 105,470 | 105,295 | 105,079 | 104,788 |
| Common Shares | 110 | 109 | 109 | 109 | 108 |
| Retained earnings | 1,748,222 | 1,495,107 | 1,230,303 | 1,018,436 | 852,700 |
| Other shareholders' equity | -13,080 | -2,951 | 5,152 | 3,886 | 8,503 |
| TOTAL | $4,449,245 | $4,491,247 | $4,076,506 | $3,765,082 | $3,654,837 |
| Total Liabilities And Equity | $6,973,466 | $6,828,019 | $6,204,906 | $5,904,460 | $5,609,132 |